Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0
|
作者：
Ducreux, M. P. [1 ]
Cheng, A-L. [2 ]
Qin, S. [3 ]
Zhu, A. X. [4 ]
Ikeda, M. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Galle, P. R. [10 ]
机构：
[1] Gustave Roussy, Med Oncol, Villejuif, France
[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan
[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea
[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782TiP
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [21] Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
    Espinoza, Magdalena
    Muquith, Maishara
    Lim, Mir
    Zhu, Hao
    Singal, Amit G.
    Hsiehchen, David
    GASTROENTEROLOGY, 2023, 165 (01) : 286 - +
  • [23] Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
    Yim, Sun Young
    Lee, Sung Hwan
    Baek, Seung-Woo
    Sohn, Bohwa
    Jeong, Yun Seong
    Kang, Sang-Hee
    Park, Kena
    Park, Hyewon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Park, Young Nyun
    Leem, Sun-Hee
    Curran, Michael A.
    Kim, Ji Hoon
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [24] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [25] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients (pts) with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Qian, Yuquan
    Liu, Baojiang
    Weiss, Christel
    Zhu, Xu
    Teufel, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 79 - 79
  • [26] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [27] Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
    Fulgenzi, Claudia A. M.
    Murphy, Cian
    D'Alessio, Antonio
    Scheiner, Bernhard
    Pinter, Matthias
    Cortellini, Alessio
    Pinato, David J. James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 597 - 597
  • [28] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024, 13 (06) : 669 - 670
  • [29] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Kubo, Akinori
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Shigesawa, Taku
    Nakamura, Akihisa
    Yamada, Ren
    Ohara, Masatsugu
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Suzuki, Kazuharu
    Izumi, Takaaki
    Meguro, Takashi
    Terashita, Katsumi
    Ito, Jun
    Miyagishima, Takuto
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 979 - 989
  • [30] Reply to correspondence on "Genomic biomarkersto predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Kanzaki, Hiroaki
    Hoshida, Yujin
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
12345